Legend Biotech Corporation (LEGN)
LEGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1801198/000180119826000008/0001801198-26-000008-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LEGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001801198 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | E9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.0B |
| Net income | -$296.8M |
| Operating income | Not in SEC XBRL data |
| Net margin | -28.8% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-18 |
| Latest annual report | 20-F | 2026-03-10 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-13 |
Source: SEC EDGAR submissions feed, 383 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | +9.0% |
| 3 months | -15.2% |
| Year to date | -11.4% |
| 1 year | -41.4% |
| From 52-week high | -46.9% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals Inc. | $26.85 | -2.29% | $3.4B |
| VKTX | Viking Therapeutics Inc. | $26.65 | -5.96% | $3.3B |
| OGN | Organon & Co. Common Stock | $13.77 | 0.00% | $3.6B |
| XENE | Xenon Pharmaceuticals Inc. Common Shares | $34.42 | -3.88% | $3.3B |
| IDYA | IDEAYA Biosciences Inc. | $34.26 | -4.99% | $3.3B |
| ARQT | Arcutis Biotherapeutics Inc. | $26.09 | -0.50% | $3.3B |
| PBLS | Parabilis Medicines Inc. | $26.85 | -7.25% | $3.3B |
| TLX | Telix Pharmaceuticals Limited | $10.92 | -3.28% | $3.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier